US/UK/Canada

Share

Pick a time period -
Tags ( Active)

The board of directors resolves to repurchase warrants series 2020/2023

The board of directors of AcouSort AB, 556824-1037 ("AcouSort", the "Company") decided on December 18, 2023, that the Company resolves to repurchase Warrants of series 2020/2023 as set out below.As of the date of the proposal, there are 282,500 outstanding warrants of series 2020/2023, each entitling the holder to subscribe for 1.015 shares in the Company at a subscription price of SEK 14.58 during the period from and including 1 September 2023 up to and including 30 December 2023. The Company shall offer to buy back a maximum of eight and a half (8.5) outstanding warrants (rounded to

AcouSort´s rights issue is registered – conversion of BTU into shares and warrants

AcouSort AB (publ) has completed a rights issue of units, consisting of shares and warrants of series TO 2 (the “Warrants”), which ended on 30 November 2023. The rights issue has today, 12 December 2023, been registered with the Swedish Companies Registration Office and the last day for trading in paid subscribed units (“BTU”) is 15 December 2023. The record date is 19 December 2023, after which the BTUs will be converted into shares and Warrants on 21 December 2023.THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES,

FDA approval paves the way for AcouSort’s first OEM commercialization within critical care diagnostics

AcouSort AB (publ) (“AcouSort”, the “Company”) today announces that the Company and its partner within critical care diagnostics have updated their collaboration agreement. The updated agreement follows the FDA approval in the fall of 2023 for the partnering company’s next generation point-of-care diagnostic system containing AcouSort’s acoustofluidics technology. Minimum revenues from the partnership in 2024 are expected to reach approximately SEK 3.5M.AcouSort and its partner within critical care diagnostics have updated their collaboration agreement, and the commercial phase of the

AcouSort's rights issue fully subscribed

AcouSort AB (publ) ("AcouSort" or the “Company") announces today the final outcome of the rights issue of units with pre-emption rights for the Company’s shareholders, consisting of shares and series TO 2 warrants, which concluded on November 30, 2023 (the “Rights Issue"). The Rights Issue has been subscribed to a total of 100.0 percent, of which approximately 70.8 percent was subscribed with the support of subscription rights and approximately 29.2 percent was subscribed without the support of subscription rights. Through the Rights Issue, AcouSort is thus receiving approximately SEK 24.8

AcouSort announces preliminary outcome of rights issue

AcouSort AB (publ) ("AcouSort" or the “Company") today announces the preliminary outcome of the rights issue of units, consisting of shares and warrants of series TO2, which was announced on 7 November 2023 (the “Rights Issue”). The preliminary outcome is that the Rights Issue has been subscribed to a total of approximately 93.4 percent, of which approximately 70.8 percent were subscribed with unit rights, approximately 22.6 percent were subscribed without unit rights. Through the Rights Issue, AcouSort is expected to receive approximately MSEK 23.2 before issuing costs.THIS PRESS RELEASE

AcouSort changes Certified Adviser to Carnegie Investment Bank AB (publ)

AcouSort today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ).AcouSort has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment Bank AB (publ) will take over as Certified Adviser on November 30, 2023. Until then, Erik Penser Bank AB will continue to act as Certified Adviser to the company.

Last day of trading in unit rights in AcouSort

Today, 27 November 2023, is the last day of trading in the unit rights issued in conjunction with AcouSort AB (publ)'s ("AcouSort" or the "Company") rights issue of units, consisting of shares and warrants, with pre-emption rights for existing shareholders which was resolved by the Board of Directors on 7 November 2023 with the support of the authorization granted by the Annual General Meeting held on 25 April 2023 (the "Rights Issue"). Unit rights that are not sold by today, 27 November 2023, or exercised for subscription of units no later than 30 November 2023, will expire worthless.THIS

AcouSort publishes an information memorandum in connection with the forthcoming rights issue of units

AcouSort AB (publ) ("AcouSort" or the "Company") today publishes an information memorandum regarding the Company's forthcoming rights issue of so-called units (“Units”) consisting of shares and warrants, resolved by the Board of Directors on 7 November 2023 (the "Rights Issue"). The information memorandum is available on the Company's website (www.acousort.com) and on Erik Penser Bank's website (www.penser.se). Upon full subscription in the Rights Issue the Company will initially receive approximately MSEK 24.8 before issuing costs.THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR

The Board of Directors’ of AcouSort resolves on a rights issue of units of approximately MSEK 24.8

The Board of Directors of AcouSort AB (publ) ("AcouSort" or the "Company") has today, with the support of the authorization granted by the Annual General Meeting held on 25 April 2023, resolved to carry out a rights issue of shares and warrants (“Units”) with pre-emption rights for the Company's shareholders (the “Rights Issue"). Each Unit consists of three shares and one free-of-charge warrant of series TO 2 (“Warrants”). The subscription price amounts to SEK 45.00 per Unit, which corresponds to SEK 15.00 per new share. Upon full subscription the Company is initially provided with

AcouSort AB - Interim Report for the period July – September 2023

Third quarter 2023 for the Group Net sales amounted to SEK 1,121,000 (326,000) Result before tax amounted to SEK -4,303,000 (-4,250,000) Result per share* was SEK -0.33 (-0.32) Equity ratio** amounted to 53% (89%) on September 30, 2023 Third quarter 2023 for the Parent company Net sales amounted to SEK 1,121,000 (326,000) Result before tax amounted to SEK -3,609,000 (-4,219,000) Result per share* was SEK -0.27 (-0.32) Equity ratio** amounted to 61% (89%) on September 30, 2023Significant events during the third quarter On July 5, AcouSort announces that the cell

High throughput cell wash for cell therapy - an important milestone towards new OEM partnerships

AcouSort’s strategy is to develop and deliver automated cell processing OEM modules that replaces several of today’s manual handling steps. The newly developed high throughput cell processing test system is directed toward the cell therapy manufacturing process and can contribute making the process more efficient and safer. The cell therapy components are for single use, which means that AcouSort sees great opportunities in establishing a significant stream of recurring revenue over time.As previously communicated, AcouSort has developed a new test system for automated cell handling within

AcouSort delivers fully functional test system for automated cell handling within cell therapy

AcouSort’s collaboration with a global life science company has reached a significant milestone with the delivery of a fully functional test system for cell therapy processing. The system is operating according to the partnering company’s requirements with the intention of being integrated into a new automated cell therapy production system.The order for the prototype was communicated in July 2023, and the unit has now been successfully delivered to the partnering company. During the installation, several researchers from the partnering company were trained on the prototype to ensure

CEO Torsten Freltoft presents AcouSort's opportunities in cell therapy and diagnostics at LSX Nordic Congress on October 10

AcouSort is an innovative medical technology company developing critical components for instrumentation used in the diagnostics, analytics, and cell therapy processing markets. The company is in early commercial phase with continuously strengthened positions in the company's focus areas – diagnostics, cell therapy and innovation.The LSX Nordic Congress is the leading senior executive strategy, investment and partnering conference for the Nordic region. It has been connecting life science and healthcare industry leaders with international investment and strategic partners to further the

AcouSort to present its unique acoustofluidics technology at the international conference µTAS 2023

AcouSort’s technology makes it possible to fractionate the different cell types in a blood sample, isolate extracellular vesicles, or wash cells to remove contaminants, without having any physical contact with the sample. The technology continues to find its way into an increasing number of life science applications. On October 15-19, 2023, AcouSort will attend µTAS 2023, the 27th International Conference on Miniaturized Systems for Chemistry and Life Sciences, to present the unique features of its technology.The µTAS 2023 conference is expected to attract some 1,000 scientists and industry

Continuously growing interest for AcouSort’s research systems

Over the past year, AcouSort has seen an increasing interest for the Company’s benchtop research systems. Most recently, AcouSort delivered and installed an AcouWash system at the Faculty of Medicine at the University of Porto, Portugal. This placement is the fifth AcouWash system delivered this year.The AcouWash system delivered to the University of Porto will be used in a research project lead by Dr Raphaël Candas. The project aims to develop new methods to isolate, detect and characterize cancer cells in urine samples, which in turn may be an important step towards developing novel

AcouSort to participate in the prestigious NIH Research Festival

AcouSort has been selected to participate in the yearly NIH Research Festival arranged by the prestigious American National Institute of Health (NIH). The event takes place September 18-22 and gathers a wide range of NIH researchers.  The research festival includes lectures, workshops, posters, and biotech vendor booths.This year’s festival is the first festival since the end of the COVID-19 pandemic. To participate as a vendor, you have to apply and be selected by the research festival committee. AcouSort has been chosen to participate in the vendor exhibition and has also been selected to

AcouSort AB - Interim Report for the period April– June 2023

Second quarter 2023 for the Group Net sales amounted to SEK 1,816,000 (715,000) Result before tax amounted to SEK -3,193,000 (-4,055,000) Result per share* was SEK -0.24 (-0.31) Equity ratio** amounted to 58% (88%) on June 30, 2023 Second quarter 2023 for the Parent company Net sales amounted to SEK 1,816,000 (715,000) Result before tax amounted to SEK -2,406,000 (-4,030,000) Result per share* was SEK -0.18 (-0.31) Equity ratio** amounted to 63% (88%) on June 30, 2023Significant events during the second quarter On April 3, AcouSort announces that the stem cell

AcouSort invited to give a lecture at the Acoustofluidics conference

AcouSort’s Senior Scientist Mikael Evander has been asked to give an invited lecture at Acoustofluidics 2023, which celebrates its 20th anniversary this year. Acoustofluidics is a conference dedicated to exploring the science, the engineering, and the use of micro and nanoscale acoustofluidics. The first conference was held in 2003 as part of a UK based network called USWnet. Today, the conference has grown into an international event gathering researchers working with all different aspects of acoustofluidics and its applications within life sciences.The opportunity to give an invited

Cell therapy collaboration with leading global life science company continues to expand

In January 2023, AcouSort reported that the company’s collaboration with a global life science company active within the cell therapy field had been extended with a second phase. The second phase of the collaboration has been brought to a successful close and the partnering company has now ordered an evaluation setup to internally assess the potential of AcouSort’s technology. The new activity will generate additional revenues of EUR 50 000 in 2023.The continued collaboration aims to in more detail explore the robustness and adaptability of AcouSort’s AcouWash technology for the partner’s

AcouSort strengthens its R&D capabilities by the recruitment of Henrik Johansson

AcouSort has recruited Henrik Johansson to the position as Director of Research and Technology. Henrik has significant experience from startup environment within the biotech space as well as from R&D management roles at Agilent and PerkinElmer. Going forward, he will play a key role in the further development of AcouSort’s technology portfolio.As Director of Research and Technology, Henrik will be responsible for AcouSort’s Research projects. Primary focus will be on managing research activities aimed at further developing and applying AcouSort’s core technology to address unmet needs

AcouSort continues its strategic collaboration with academia– delivers a unique AcouWash 2 system to Lund University

In the autumn of 2022, AcouSort received an order from Lund University for the development of a modified AcouWash 2 system, custom-designed to support the separation of circulating tumor cells (CTC) from white blood cells. The project will generate revenues of SEK 500,000 in 2023.The unique pre-focusing feature of the modified AcouWash 2 system enables high-precision separation and will be used to extract CTC from patient samples in a project at Lund University. The high-precision capability allows for a range of new applications within research and diagnostics, including the separation of

AcouSort AB - Interim Report for the period January – March 2023

First quarter 2023 for the Group · Net sales amounted to SEK 2,598,000 (1,892,000) · Result before tax amounted to SEK -3,040,000 (-2,652,000) · Result per share was SEK -0.23 (-0.20) · Equity ratio amounted to 62% (90%) on March 31, 2023 First quarter 2023 for the Parent company · Net sales amounted to SEK 2,560,000 (1,892,000) · Result before tax amounted to SEK -2,285,000 (-2,613,000) · Result per share was SEK -0.17 (-0.20) · Equity ratio amounted to 64% (90%) on March 31, 2023Significant events during the first quarter On January 19, AcouSort announces

AcouSort launches next generation AcouTrap at CYTO 2023

CYTO is organized by the International Society for the Advancement of Cytometry and attended by leading researchers and instrumentation providers within flow cytometry. This year, AcouSort will use the conference to launch the new and much improved AcouTrap system. The conference is held in Montréal, Canada, May 20-24.The new AcouTrap 3 system comes with improved design and an updated and intuitive software graphical user interface (GUI), which simplifies user workflows. The new design and new software are based on customer feedback from AcouSort’s last generation of AcouTrap. Along with

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe